Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry &...

57
Peter S. Jensen, MD Peter S. Jensen, MD President & CEO President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children: Evidence, Best Practices, and Getting there from Here

Transcript of Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry &...

Page 1: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Peter S. Jensen, MDPeter S. Jensen, MDPresident & CEOPresident & CEO

The REACH Institute

Co-Chair, Division of Child Psychiatry & Psychology

The MAYO CLINIC

Medications in Young Children: Evidence, Best Practices,

and Getting there from Here

Page 2: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Evidence for Medications in C&A Disorders

STRONGSTRONGADHDADHD StimulantsStimulants

TCAsTCAsATXATX MODERATEMODERATE

WEAKWEAK

DEPRESSIONDEPRESSION SSRIsSSRIs

AUTISM AUTISM AntipsychoticsAntipsychotics

OCDOCD SSRIs, TCAsSSRIs, TCAs

ODD/CD/AggODD/CD/Agg Antipsychotics, Mood stabilizers, Antipsychotics, Mood stabilizers, StimulantsStimulants

ANXIETYANXIETY SSRIsSSRIs

BIPOLAR/SZBIPOLAR/SZ AtypicalssAtypicalss BIPOLAR BIPOLAR Lithium Lithium

TOURETTE’S AntipsychoticsTOURETTE’S Antipsychotics

Page 3: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Three Levels:

Child & Family Factors:

e.g., Access & Acceptance

Provider/Organization Factors:

e.g., Skills, Use of EB

Systemic and Societal Factors:

e.g., Organiz., Funding Policies

Barriers vs. “Promoters” to Barriers vs. “Promoters” to Delivery of Effective Services Delivery of Effective Services

(Jensen, 2000)(Jensen, 2000)

“Effective”

Services

Efficacious Treatments

Page 4: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

4

% “Normalized” at 14-month Endpoint% “Normalized” at 14-month EndpointMTA Groups vs. Classroom ControlsMTA Groups vs. Classroom Controls

88%

68%

56%

34%25%

MTA N = 579, Classroom Cntrls N = 288

1. MTA Co-operative Group Arch Gen Psychiatry 1999 56: 1073–1086

Page 5: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

14-Month Outcomes 14-Month Outcomes

Teacher SNAP-InattentionTeacher SNAP-Inattention

0

0.5

1

1.5

2

2.5

3

0 100 200 300 400

CC

Beh

MedMgt

Comb

Time x Tx: F=10.6, p<.0001Site x Tx: F=0.9, nsSite: F=2.7, p<.02

Comb, MedMgt > Beh, CC

Avera

ge S

core

Assessment Point (Days)

Page 6: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Would You Recommend Treatment? (parent)

Medmgt Comb Beh

Not recommend 9% 3% 5%

Neutral 9% 1% 2%

Slightly Recommend 4% 2% 2%

Recommend 35% 15% 24%

Strongly recommend 43% 79% 67%

Page 7: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

0.5

1

1.5

2

2.5

0 100 200 300 400

Assessment Point (Days)

Ave

rage

Sco

re

CC-NOMEDS

CC-MEDS

BEH

MED

COMB

Key Differences,

MedMgt vs. CC:

Initial Titration

Dose

Dose Frequency

#Visits/year

Length of Visits

Contact w/schools

Teacher-Rated InattentionTeacher-Rated Inattention(CC Children Separated By Med (CC Children Separated By Med

Use)Use)

Page 8: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Case StudyNew York Times, 2007 (Carey)

• 4 year-old girl

• ADHD + Bipolar diagnosis age 2

• Seroquel (atypical AP)

• Depakoate (mood stabilizer/seizure agent

• Clonidine

• No studies of any of these agents in children under age 6

Page 9: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Trends over Time in Preschool Prescribing

• Minde, 1997: US and Canada– 3-fold increases in Methylphenidate– 10-fold increases in SSRIs

• Zito 2000– State Medicaid claims, 2 states– 1.5% of children ages 2-5, significant increases over time– 28-fold increases in clonidine– 3-fold increases in MPH

• Recent increases in atypicals in preschoolers• Majority of preschool meds – stimulants• Most preschoolers w/behavior problems get therapy only

Page 10: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Case Example:ADHD in Preschoolers

• DSM-IV criteria same in younger children– Triad of impulsivity, inattention, hyperactivity– Developmental considerations

• Clinical presentation– Frequent comorbidity (74%) – Wilens et al., 2002)– CD, ODD, Anxiety– Only 19% received services (Pavuluri et al., 1996)

Page 11: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

PATS: The Preschool ADHD Treatment Study

• Only one dozen small trials in preschool children, total N = 417 (Ghuman et al., 2008)

• Variable results, increased side effects– Sadness, irritability, clinging, insomnia,

anorexia

• PATS intended to fill the gap of information in a sufficiently large trial

Page 12: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

PATS: The Preschool ADHD Treatment Study

• 8 phase study, 70 weeks• 303 preschool children ages 3-5.5 yrs• All began with 10 week group parent training• 70% comorbidity

– Increased ADHD severity linked to anxiety, depression

• Non-responders eligible for next phase (MPH), N = 165

• Graduated dose-response, 14.2mg/day MPH

Page 13: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

PATS: The Preschool ADHD Treatment Study

• 2.5, 5, and 7.5mg given t.i.d.• Effect sizes smaller than older children

– Less weight gain -1.32 kg/year among medicated children– Less height gain -1.38 cm/year among medicated children

• No serious side effects– Irritability, outbursts, DFA, reduced appetite

• Slower renal clearance than older children• Multiple comorbidities – little or no response• 140 children complete 10 months, 45 discontinue meds

Page 14: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

PATS: The Preschool ADHD Treatment Study

Page 15: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

PATS: The Preschool ADHD Treatment Study

Study month

Page 16: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Other Preschool ADHD Studies

• Atomoxetine (Strattera) open study given to 22 5-6 year olds

• Apparent benefits, 1.25mg/kg/day

• No serious side effects

• Role of psychosocial treatments paramount

• Possible benefit of combination approaches, especially innovative new therapy approaches

• Some evidence for dietary approaches

Page 17: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Preschool ADHD Therapy Studies

• Family factors critical to ADHD outcomes– Negative or inconsistent parenting, harsh

discipline, or high levels of family adversity

• However, only 7.2% of 261 PATS families benefited significantly from PT alone

• Home-based parent training using innovative approaches more effective than medication at 1 year (Sonuga-Barke et al., 2001)

Page 18: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Guidelines Relevant Medication Use in Preschoolers

• Practice Parameters for Psychiatric Assessment of Infants & Toddlers (AACAP, 1997)– Establishing a working alliance– Reasons for referral– Developmental history– Family relational history– Clinical observation– Standardized tools– Mental status exam– Interdisciplinary assessment & referral– Diagnostic formulation– Treatment planning

Page 19: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Guidelines Relevant to Medication Use in Preschoolers

Practice Parameters for Use of Psychotropic Medications in C&A (AACAP, 2009)

1) Before starting meds, do complete psychiatric evaluation

2) Before starting meds, do med Hx and evaluation

3) Communicate w/other professionals to plan/coordinate care

4) Develop psychosocial and pharmacologic treatment plan

5) Develop/implement short- and long-term monitoring plan

6) Be cautious when implementing plan that can’t be monitored

Page 20: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Guidelines Relevant to Medication Use in Preschoolers

Practice Parameters for Use of Psychotropic Medications in C&A (AACAP, 2009) (continued)

7) Complete and document assess and consent

8) Discuss risks and benefits

9) Use adequate dose and duration

10) Reassess for incomplete or non-response

11) Provide clear rationale for medication combinations

12) Discontinuation requires clear plan

Page 21: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Guidelines Relevant to Medication Use in Preschoolers

• Psychopharmacologic Treatment for Very Young Children Contexts and Guidelines (Gleason et al., 2007)

– Avoid meds when therapy is likely to be helpful– Precede meds with an adequate trial of therapy– Continue psychotherapy even when meds are used

– ADHD Algorithm stages• STAGE 0 DIAGNOSTIC EVAL AND THERAPY TRIAL

• STAGE 1 PHARMACOLOGIC TRIAL (MPH)

• STAGE 2 AMPHETAMINE TRIAL

• STAGE 3 ALPHA AGONIST OR ATOMOXETINE

Page 22: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Guidelines Relevant to Medication Use in Preschoolers

• Psychopharmacologic Treatment for Very Young Children Contexts and Guidelines (Gleason et al., 2007)

– DISRUPTIVE DISORDER Algorithm stages• STAGE 0 DIAGNOSTIC EVAL• STAGE 1 NON-PHARMACOLOGIC INTERVENTIONS• STAGE 2 RISPERIDONE TRIAL, CONTINUE THERAPY

– DEPRESSIVE DISORDER Algorithm stages• STAGE 0 DIAGNOSTIC EVAL• STAGE 1 NON-PHARMACOLOGIC INTERVENTIONS• STAGE 2 SSRI TRIAL(S), CONTINUE THERAPY

Page 23: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Guidelines Relevant to Medication Use in Preschoolers

• Psychopharmacologic Treatment for Very Young Children Contexts and Guidelines (Gleason et al., 2007)

– BIPOLAR DISORDER Algorithm stages• STAGE 0 DIAGNOSTIC EVAL• STAGE 1 NON-PHARMACOLOGIC INTERVENTIONS• STAGE 2 MEDICATION TRIAL(S), CONTINUE THERAPY• NOT RECOMMENDED: MEDS W/O THERAPY

– ANXIETY DISORDER Algorithm stages• STAGE 0 DIAGNOSTIC EVAL• STAGE 1 NON-PHARMACOLOGIC INTERVENTIONS• STAGE 2 FLUOXETINE TRIAL, CONTINUE THERAPY• STAGE 3 FLUVOXAMINE TRIAL, CONTINUE THERAPY

Page 24: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Guidelines Relevant to Medication Use in Preschoolers

• Psychopharmacologic Treatment for Very Young Children Contexts and Guidelines (Gleason et al., 2007)

– PDD DISORDERS Algorithm stages• STAGE 0 DIAGNOSTIC EVAL• STAGE 1 NON-PHARMACOLOGIC INTERVENTIONS• STAGE 2 MEDICATION TRIAL(S), CONTINUE THERAPY

– SLEEP DISORDERS Algorithm stages• STAGE 0 DIAGNOSTIC EVAL• STAGE 1 NON-PHARMACOLOGIC INTERVENTIONS• STAGE 2 MELATONIN TRIAL, CONTINUE THERAPY• STAGE 3 CLONIDINE TRIAL, CONTINUE THERAPY

Page 25: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

The PROBLEM:

• Desperate parents & preschools

• Limited resources

• Need for effective education of providers– Current CME methods ineffective– Educational materials (e.g., distribution of

recommendations for clinical care, including practice guidelines, AV materials, and electronic publications)

– Didactic educational meetings

Page 26: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Effective Provider & Organizational Interventions:

• Educational outreach visits

• Reminders (manual or computerized)

• Multifaceted interventions

• Sustained, interactive educational meetings (participation of providers in workshops that include discussion and practice)

Bero et al, 1998

Page 27: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Dissemination and Adoption of New Interventions

Dissemination and Adoption of New Interventions

Sustained Interpersonal contact Organizational support Persistent championship of the intervention Adaptability of the intervention to local

situations Availability of credible evidence of success Ongoing technical assistance, consultation

Page 28: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Implications re: Changing Provider Behaviors

• Changing professional performance is complex - internal, external, and enabling factors

• No “magic bullets” to change practice in all circumstances and settings (Oxman, 1995)

• Multifaceted interventions targeting different barriers more effective than single interventions (Davis, 1999)

• Consensus guidelines approach necessary, but not sufficient.

• Lack of fit w/HCP’s mental models

Page 29: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

29

End Result: Families not getting the evidence-based assistance they need

• Many proven treatments now available but…

– Information is not getting to families, health care providers and schools

– It takes anywhere from 15-20 years for a proven intervention to reach a PCC who will use it to treat your child

• Information and assistance needs to be– Family friendly– Guided by family input and

experience– Science-based– Practical and hands-on

Page 30: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

30

Manpower Problems• Scarcity of Child Psychiatry• Boutique practices• Differences in care based on ability to pay• Pseudo-Stradavarius model vs. High quality production model• 6000 CAPs, 5000 active, for 7 million children:

– 1,400 children per CAP, vs. 50-200 seen per year – 10 hours/year spread across 2000 hours = 200 children– Only 1 in 7 children seen by CAPs -- 14%.

• If all CAPs time were spread equally across all children in need = 1.5 hours child… (four 15’ med-checks/year)

• Alternatives?

Page 31: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

31

Quality Problems• Diagnostic practices

– Unreliability of individual clinicians– Variabilty of diagnostic and treatment practices– 8-fold increases in bipolar– Polypharmacy– Lack of dissemination of EBPs (Evidence-based practices)– Failure to use EBAIs(evidence-based assessments & interventions)

• Novice families don’t know how to discriminate quality!– Relationship key, but only partial indicator of quality

• Alternative Solutions?

Page 32: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Accelerating this process:

The REsource for Advancing Children’s Health:

The REACH Institute

Page 33: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

33

The REACH Institute ~ Putting Science to Work ~

• Promoting a family-oriented approach to mental health care

• Developing partnerships with parents, pediatricians, APRNs, schools, and others to apply best practices and proven interventions

• Providing “hands-on” assistance to partners

• Focusing on Key Disorder Areas

The Institute was established in the spring of 2006 to accelerate the acceptance and effective use of proven interventions that foster children’s emotional and behavioral health.

REACH fills a unique role by:

Page 34: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

34

Training in What?

• Parent/Family Level: Parent Facilitators

• Clinician Level: Increasing positive and/or proven practices, reducing potentially harmful, unnecessary/expensive practices Brief Psychotherapy manuals and training on treatment

for anxiety, depression, trauma, and conduct problems Pediatric Psychopharmacology Mini-fellowship Engagement training EB Assessments/Diagnosis

• Systems Level: consultation & reorganization

Page 35: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

35

Training, But How?

• CME and “hit and run” workshops generally ineffective

• Training needs to address issues and obstacles that are likely to be encountered at ALL THREE levels

• Collaborative learning partnership approaches, vs. one-down relationships

Page 36: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Recommended methods for assisting health care staff in adopting EBPs

Training Method

Mean SD Median Mode

Reading 3.00 1.61 3 3

Brief video-based training

4.12 2.48 4 1

Supervisor consultation

4.58 2.09 5 5

Didactic workshops no follow-up

4.89 2.69 5 6

Consultation with experts

5.89 2.40 6 6

Hands on workshops with follow-up

8.45 1.35 9 9

Page 37: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

37

Step 1

Identify and Validate

• Identify key problem areas w/partners

• Obtain consensus & commitment on the latest, most effective interventions derived from rigorous research

REACH Approach: A 4-step processStep 2

Adapt

• Make interventions “user-,” “patient-” and “family-friendly”

• …so they can be readily applied by patients, families, and health care professionals

Step 3

Distribute, Apply and Evaluate

• Use strategic learning partnerships

• Reach as many children as possible in a credible and effective way

• Evaluate, feed results back into Step 2

Step 4

Empower

• Strategic partners carry forward the mission to their own organization members, to enable proven interventions to reach the most kids in the shortest time

Page 38: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Training Approach

• Hands-on, with role plays and extensive practice

• Can be done “on-site” or at national locations

• 2 day’s face-to-face training with 15-30 clinicians, with 2-3 trainers, followed by:

• 6 months of twice-monthly phone call consultation and support, 1-1.5 hours/call

• Individual case presentations, with peer learning

Page 39: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Training Benefits

• Graduates report improved staff morale, decreased staff burn-out and turn--over

• Risk management & quality assurance

• Decreased no-show rates, improved billing

• Increased treatment efficacy and improved family/student/client satisfaction

• Enhanced value-added of current services

• “Excellence” certificates for clinicians & educators after completing training

Page 40: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

40

Example 1: Primary Care Providers: “Best Practices”

• Deliver family-centered, effective care

Partner with doctors and APRNs to identify and implement “Best Practices.”

• Assist pediatricians and family practitioners to manage youth depression and suicide risk

• Help doctors in managing treating ADHD and Depression, and avoiding over-diagnosis

• Help doctors get the right information to patients and families

• Pediatric Psychopharmacology Program – – A “Mini-Fellowship”– 6 months’ training and support

Page 41: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

41

Example 2: Helping Therapists Apply “EBPs”

Training Partnerships with counselors and psychotherapists to apply CBT, IPT, Engagement Strategies, BT

• Uniform ‘look and feel’: same introduction, supporting documentation (CBT) and introductory session.

• Manuals share similar session structure, graphics and session markers

• One year of supervision• Organizational Partnership• Evaluation Partnership

Page 42: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

REACH’s Integrated Psychotherapy Consortium

• Anxiety: Tom Ollendick, Ron Rapee, Wendy Silverman

• Depression: Kevin Stark, John Curry

• Disruptive: John Lochman, Karen Wells

• PTSD: Chris Layne, William Saltzman

• Consultant: Bruce Chorpita

• REACH Institute: Peter Jensen, Eliot Goldman, Kimberly Hoagwood

Page 43: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

The REACH - Integrated Psychotherapy Approach

• Manuals originally developed for Project Liberty (mental health response to 9/11 trauma)

• Intervention geared to children & adolescents with mild/moderate sx

• 4 areas of intervention (anxiety, depression, disruptive & PTSD)

• Adapted from evidence based tx developed by nationally recognized experts

Page 44: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Termination Session

Anxiety Depression AggressionPTSD

End

Begin

Optional Sessions

Page 45: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Common techniques to aid in training and clinical applicability• Problem solving

• Social skills

• Family sessions

• Setting goals

• Organizational skills

Page 46: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Session Markers

5 minutesTimed Section

Exercise

Graphic

Also sample language, session goals

Page 47: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

How are you feeling today ?

Page 48: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:
Page 49: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Example 3: Engagement Training

• Explicit problem-solving approach applied by health care team concerning the family’s perceived obstacles to care

• Tailoring to fit specific needs and family values

• Respect of mutual expertise

• Encouragement of ventilation of concerns & questions

• Dramatic reductions in no-show rates

• Increased effects with psychoeducation, also increased satisfaction and compliance

• SAVES CLINIC AND CLINICIAN TIME!

Page 50: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Example 4: Parent Empowerment Training

• Uses Professional Parent Advocates to model and teach parents how to navigate the system, advocate for their child, and get high quality evidence-based care

• Promote parent/provider partnerships• Increase parent knowledge about mental

health needs and evidenced based service delivery options

• Increase parent self efficacy• Improve parent communication and

assertiveness skills

Page 51: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

51

Examples of Parent Activities

• Learning about specific disorders and their evidenced-based treatments

• How to keep a mental health “notebook” for your child

• How to respond assertively to your child’s clinician

Page 52: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

52

Example 5: School Interventions

Focused on Improved Academic and School Behavior Outcomes

• Guided, created and delivered by national team of educational and mental health experts

• School-wide approaches, such as training in optimal classroom behavioral management, social-emotional curricula, violence prevention, and anti-bullying programs

• Programs to help school staff identify and effectively help children with MH needs

• Training in CBT and latest MH therapies

Page 53: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

MH Services Reform: Strategic Issues

Training, TA, & Time

Training, TA, & Time

Training, TA, & Time

Page 54: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

Science-based Plus Necessary “-abilities”

• Palatable (acceptable to families and clinicians)• Affordable• Transportable• Trainable• Adaptable, Flexible• Evaluable • Feasible• Sustainable

Page 55: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

MH Services Reform: Strategic Issues

• Leadership, trust, engagement, and therapeutic alliance factors critical at all levels of “the system”

• Begin with the end in mind: establish and ensure necessary “abilities” at all 3 levels

• Enemy of the good is the perfect: raise the floor, not the ceiling

• Win-win strategies

• ”Buy-in” -- partnership, not ownership

Page 56: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

MH Services Reform: Next Steps

• Evidence Based Guidelines• Child/Youth Empowerment and Support• Parent Empowerment and Support• MH Screening and Assessment• Psychosocial Interventions• Psychopharmacologic Standards and Procedures

• EB Training – sufficient to produce & sustain behav change in clinicians and systems, and parents to become “agents of change”

• WWW.TheREACHInstitute.org• [email protected]

Page 57: Peter S. Jensen, MD President & CEO The REACH Institute Co-Chair, Division of Child Psychiatry & Psychology The MAYO CLINIC Medications in Young Children:

57

The REACH Institute

REsource for Advancing Children’s Health

The REACH Institute

REsource for Advancing Children’s Health